News and Trends 25 May 2023 PharmEnable raises $7.5M to develop small molecule drugs to treat cancer and neurological diseases PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi […] May 25, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2023 Researchers discover genetic variation offers Alzheimer’s disease clues A new study conducted by researchers at the University of Eastern Finland discovered that the APP A673T genetic variant, which protects against Alzheimer’s disease (AD), alters levels of several proteins and peptides linked to amyloid-beta metabolism in human biofluids and cell culture models, including amyloid beta itself. These new data support the idea that even […] May 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2023 smartbax raises €1.2M to create next-generation antibiotics smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million ($1.3 million) from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), bringing smartbax’s total capital raised to €1.9 million ($2.1 million). The funds will be used to advance smartbax’s small molecule […] May 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2023 Major progress as Swedish scientists get brain tumors to self destruct Researchers at the University of Gothenburg in Sweden, working with French colleagues, have successfully developed a method able to kill the aggressive brain tumor glioblastoma. By blocking certain functions in the cell with a docked molecule, the researchers cause the cancer to die of stress.Cancer cells, especially those that form aggressive tumors, are in one […] May 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 FDA approval for Rznomics’ glioblastoma treatment trial Rznomics Inc., a South Korea based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, has received phase 1/2a IND approval from the U.S. FDA for its glioblastoma multiforme (GBM) treatment. RZ-001 initially obtained IND approval for hepatocellular carcinoma (HCC), but Rznomics also found pre-clinical efficacy in GBM models and submitted the IND for […] May 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 AMR research gets £39m shot from UK government Research initiatives to develop new treatments to tackle antimicrobial resistance (AMR) – known as the “silent killer” – will receive a cash injection of up to £39 million ($48.5 million) from the U.K. government’s Global AMR Innovation Fund (GAMRIF). However, according to the director of Global Health Policy and Senior Policy Fellow at the Center […] May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 Vicore reports new data from idiopathic pulmonary fibrosis study Vicore Pharma Holding AB (publ), has announced an updated interim analysis of its AIR phase 2a trial with C21 in idiopathic pulmonary fibrosis (IPF). With 51 patients enrolled, the data demonstrates that C21 has the potential to transform the treatment of IPF and restore lung function. The disease is currently considered to be incurable and […] May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor HuidaGene Therapeutics, a clinical-stage genome-editing company, says the National Science Review has published data from its study of the world’s first DNA base editor converting guanine to cytosine/thymine (pyrimidine), or G-to-Y. The company has filed an international patent application for the glycosylase-based guanine base editor (gGBE) and owns the exclusive global rights to the underlying […] May 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 Ironwood acquires VectivBio in $1B deal Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, and VectivBio Holding AG, a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of approximately $1 billion, net of VectivBio […] May 23, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 Take part in a clinical trial? Sure, just pay me The majority of people in the U.K. (68%) would consider taking part in a clinical trial, it has been revealed today, while half of Brits would also be willing to take part in an early phase clinical trial. Financial payment is the most popular motivation for taking part in a clinical trial, but discovering new […] May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2023 Cancer implications as new molecule can kill ‘zombie’ cells Over time, the body’s cells stop working properly and begin to accumulate, which eventually leads to tissues aging. Researchers at the UOC (Universitat Oberta de Catalunya) in Spain, in collaboration with the University of Leicester in the U.K. have discovered a new molecule that is able to destroy these old cells without affecting healthy ones. […] May 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2023 FDA approves first topical gene therapy for dystrophic epidermolysis bullosa wound treatment The U.S. Food and Drug Administration has approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. The approval of Vyjuvek was granted to […] May 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email